A claudin 3 and claudin 4-targeted clostridium perfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells

Cancer Letters

Volumn 351, Issue 2, 2014, Pages 260-264

  Romanov, Victor ^a   Whyard, Terry C ^a   Waltzer, Wayne C ^a   Gabig, Theodore G ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Claudins; Clostridium perfringens enterotoxin; Prostate cancer; Prostate specific antigen; Protoxin

Indexed keywords

CLAUDIN 3; CLAUDIN 4; PROSTATE SPECIFIC ANTIGEN; PROTOXIN; CLDN3 PROTEIN, HUMAN; CLDN4 PROTEIN, HUMAN; ENTEROTOXIN; ENTEROTOXIN, CLOSTRIDIUM; HYBRID PROTEIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL DESTRUCTION; AMINO ACID SEQUENCE; BIOSYNTHESIS; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR CLONING; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

CLOSTRIDIUM PERFRINGENS;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CLAUDIN-3; CLAUDIN-4; CLONING, MOLECULAR; CLOSTRIDIUM PERFRINGENS; ENTEROTOXINS; HUMANS; KALLIKREINS; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 84904759862     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.06.009     Document Type: Article

References (21)

1. Dubois C., et al. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium. FEBS J. 2013.
2. Huang J.K., et al. Effect of thapsigargin on Ca(2)+ fluxes and viability in human prostate cancer cells. J. Recept. Signal Transduct. Res. 2011, 31(3):247-255.
3. Landers K.A., et al. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br. J. Cancer 2008, 99(3):491-501.
4. Walther W., et al. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther. 2012, 19(5):494-503.
5. Meng J., et al. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm. Cancer 2011, 2(3):145-156.
6. Long H., et al. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001, 61(21):7878-7881.
7. Fernandez Miyakawa M.E., et al. Clostridium perfringens enterotoxin damages the human intestine in vitro. Infect. Immun. 2005, 73(12):8407-8410.
8. Shrestha A., McClane B.A. Human claudin-8 and -14 are receptors capable of conveying the cytotoxic effects of Clostridium perfringens enterotoxin. MBio 2013, 4(1).
9. Robertson S.L., Smedley J.G., McClane B.A. Identification of a claudin-4 residue important for mediating the host cell binding and action of Clostridium perfringens enterotoxin. Infect. Immun. 2010, 78(1):505-517.
10. Winkler L., et al. Molecular determinants of the interaction between Clostridium perfringens enterotoxin fragments and claudin-3. J. Biol. Chem. 2009, 284(28):18863-18872.
11. Wu T.T., et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer 1998, 77(6):887-894.
12. Turksen K. Claudins and cancer stem cells. Stem Cell Rev. 2011, 7(4):797-798.
13. Gallardo-Williams M.T., et al. Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid. Prostate 2003, 54(1):44-49.
14. Gao Z., McClane B.A. Use of Clostridium perfringens enterotoxin and the enterotoxin receptor-binding domain (C-CPE) for cancer treatment: opportunities and challenges. J. Toxicol. 2012, 2012:981626.
15. Robertson S.L., McClane B.A. Interactions between Clostridium perfringens enterotoxin and claudins. Methods Mol. Biol. 2011, 762:63-75.
16. Erster O., et al. Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J. Control. Release 2012, 161(3):804-812.
17. Romanov V., et al. Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. Arch. Toxicol. 2014.
18. Maeda T., et al. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer. Prostate 2012, 72(4):351-360.
19. Chakrabarti G., Zhou X., McClane B.A. Death pathways activated in CaCo-2 cells by Clostridium perfringens enterotoxin. Infect. Immun. 2003, 71(8):4260-4270.
20. Singh U., et al. Comparative biochemical and immunocytochemical studies reveal differences in the effects of Clostridium perfringens enterotoxin on polarized CaCo-2 cells versus Vero cells. J. Biol. Chem. 2001, 276(36):33402-33412.
21. Denmeade S.R., et al. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 1998, 58(12):2537-2540.